Company Overview and News

 
Market Live: Sensex under pressure; SBI lifts PSU Bank over 3%, metals lose shine

3h moneycontrol
Market Update: The market remained mildly under pressure, with the Nifty falling below the 10,500 levels following weakness in global stocks.

 
Jet Air, Tata Motors, IFCI results on Wednesday

15h thehindubusinessline
About 75 companies including Aries Agro, Atlas Cycles, Bajaj Electricals, CESC, Cosmo Films, Dhanlaxmi Bank, eClerx, Entertainment Network, Eros, Finolex, GE T&D, Godrej Industries, Grasim, GVK Power, HG Infra, IFCI, Indraprastha Gas, Jet Airways, Jain Irrigation, KPIT Tech, L&T Infotech, MEP Infra, Natco Pharma, Omaxe, Ramco Cements, Repco Home, Shipping Corp, SML Isuzu, Suntech Realty, Tata Motors and Vidhi Specialty will declare their quarter and full-year results on Wednesday.

 
Natco Pharma Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Natco Pharma Limited - Trading Window

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Natco Pharma: Tonic for growth

2018-05-06 premium.thehindubusinessline
The past few years have been docile for Indian pharma companies. Regulatory tightening, coupled with multiple headwinds in the key markets, have not augured well for Indian drug makers.

 
Natco Pharma Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Closing Bell: Sensex rises 578 pts, Nifty above 10,300 as RBI holds policy rates, cuts inflation forecast

2018-04-05 moneycontrol
3:30 pm Market Closing: Benchmark indices closed sharply higher on Thursday, with the Sensex rising 577.73 points or 1.75 percent to 33,596.80, and the Nifty gaining 196.80 points or 1.94 percent at 10,325.20.

 
Market Live: Sensex jumps over 400 pts ahead of RBI policy; all sectoral indices in the green

2018-04-05 moneycontrol
10:50 am Board Meeting: ICICI Securities said the board of directors will consider approval of the audited annual accounts & financial results of the company for the financial year ended March 2018 and consider the recommendation of dividend, if any, on the equity shares for the financial year ended March 31, 2018 at its meeting to be held on April 14, 2018.

 
Market Live: Sensex jumps 350 pts ahead of RBI policy; all sectoral indices in the green

2018-04-05 moneycontrol
10:07 am Market Update: Benchmark indices remained strong as the Sensex was up 400.97 points or 1.21 percent at 33,420.04 and the Nifty gained 131.30 points or 1.30 percent at 10,259.70.

 
Natco Pharma rises 3% on launch of first generic version of Teriflunomide

2018-04-05 moneycontrol
Shares of Natco Pharma rose 3 percent in the early trade on Thursday as it launched first generic version of Teriflunomide.

 
Will new drug launch lift Natco Pharma?

2018-04-04 thehindubusinessline
Natco Pharma on Wednesday launched a generic version of Teriflunomide for the treatment of relapsing and remitting forms of multiple sclerosis (RRMS), under its brand Denopsy.

 
Natco launches generic version of multiple sclerosis drug in India

2018-04-04 moneycontrol
Drug firm Natco Pharma today said it has launched a generic version of Teriflunomide tablets used for the treatment of relapsing and remitting forms of multiple sclerosis in India.

 
Natco Pharma Limited - Press Release

2018-04-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Celgene, Prothena Partner on Neurodegenerative Treatments

2018-03-24 genengnews
Celgene will partner with Prothena to develop new treatments for neurodegenerative disorders. Including Alzheimer’s disease, through a collaboration that Prothena said could generate for it up to $150 million-plus—but which could yield more than $2 billion for the Irish-based biotech.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...